"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 5 | 7 |
| 2006 | 1 | 2 | 3 |
| 2007 | 3 | 1 | 4 |
| 2008 | 6 | 1 | 7 |
| 2009 | 7 | 4 | 11 |
| 2010 | 5 | 2 | 7 |
| 2011 | 10 | 1 | 11 |
| 2012 | 2 | 10 | 12 |
| 2013 | 6 | 4 | 10 |
| 2014 | 5 | 4 | 9 |
| 2015 | 10 | 4 | 14 |
| 2016 | 12 | 0 | 12 |
| 2017 | 3 | 6 | 9 |
| 2018 | 6 | 0 | 6 |
| 2019 | 6 | 2 | 8 |
| 2020 | 4 | 3 | 7 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
-
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance. J Virol. 2025 Feb 25; 99(2):e0173024.
-
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024 12 06; 16(12).
-
Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS. 2024 Dec 01; 38(15):2073-2085.
-
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine. Viruses. 2024 Sep 20; 16(9).
-
Performance of an in-house multiplex PCR assay for HIV-1 drug resistance testing - A cheaper alternative. J Virol Methods. 2024 Dec; 330:115034.
-
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial. J Acquir Immune Defic Syndr. 2024 Aug; 96(4):385-392.
-
Recommendations on data sharing in HIV drug resistance research. PLoS Med. 2023 Sep; 20(9):e1004293.
-
Resistance is common in paediatric patients failing ART in South Africa. J Antimicrob Chemother. 2023 05 03; 78(5):1160-1167.
-
High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study. J Acquir Immune Defic Syndr. 2022 10 01; 91(2):130-137.